secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inogen Inc (INGN)
CIK:        0001294133
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0000950170-24-060589
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inogen CMO Stanislav Glezer departs; severance includes 12-month salary & COBRA
-------------------------------------------------------------------------------

- Dr. Stanislav Glezer separated as EVP R&D and Chief Medical Officer effective April 11, 2024.
- Severance: 12 months base salary of $505,000 (26 pay periods) and COBRA premium reimbursement for 12 months.
- Unvested equity awards forfeited; vested stock options remain exercisable per plan terms.
- No annual bonus owed; tuition repayment for CEO program waived.
- Separation agreement includes standard release of claims and confidentiality obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1294133/000095017024060589/0000950170-24-060589-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1294133/000095017024060589/ingn-20240510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-060589

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer